I couldn't agree more. I haven't looked at the protocol for this trial so take with a grain of salt, but, the consistent contributors to trial slowness are recruitment pace and measurement challenges that lead to longer observation protocols.

Most trials now assume 1.5 to 2.0 years just to find the trial participants. In a study like this where they are seeking PD patients with GBA mutations, it won't be a surprise that it could take longer. The second contributing factor is measurement challenges. Lack of objective, non-clinical biomarkers means we have to track folks over a period of time longer than otherwise to see if progression is demonstrably slowed.

Patients who participate in studies (interventional ones like this or observational ones like PPMI where we are looking for GBA carriers as well as objective measures of disease progression) can contribute to more informed results coming faster.

Debi